Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 17, 2008 - Issue 1
Submit an article Journal homepage
277
Views
17
CrossRef citations to date
0
Altmetric
Drug Evaluations

Iloperidone: a new benzisoxazole atypical antipsychotic drug. Is it novel enough to impact the crowded atypical antipsychotic market?

Lawrence James Albers University of California at Irvine, Department of Psychiatry, Long Beach VA Healthcare System, 5901 East Seventh Street, Long Beach, CA 90822, USA
, MD,
Alessandro Musenga University of Bologna, Laboratory of Pharmaco-Toxicological Analysis, Department of Pharmaceutical Sciences, Via Belmeloro 6, 40126 Bologna, Italy +39 0512099740; [email protected]
, PharmD &
Maria Augusta Raggi University of Bologna, Laboratory of Pharmaco-Toxicological Analysis, Department of Pharmaceutical Sciences, Via Belmeloro 6, 40126 Bologna, Italy +39 0512099740; [email protected]
Pages 61-75 | Published online: 20 Dec 2007

Citations (17)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (5)

Frank I Tarazi & Stephen M Stahl. (2012) Iloperidone, asenapine and lurasidone: a primer on their current status. Expert Opinion on Pharmacotherapy 13:13, pages 1911-1922.
Read now
Jose de Leon, Vincenza Santoro, Concetta D'Arrigo & Edoardo Spina. (2012) Interactions between antiepileptics and second-generation antipsychotics. Expert Opinion on Drug Metabolism & Toxicology 8:3, pages 311-334.
Read now
Leslie Citrome. (2010) Iloperidone: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability, regulatory affairs, and an opinion. Expert Opinion on Drug Metabolism & Toxicology 6:12, pages 1551-1564.
Read now
Silvio Caccia, Luca Pasina & Alessandro Nobili. (2010) New atypical antipsychotics for schizophrenia: iloperidone. Drug Design, Development and Therapy 4, pages 33-48.
Read now
Robin Emsley. (2009) Drugs in development for the treatment of schizophrenia. Expert Opinion on Investigational Drugs 18:8, pages 1103-1118.
Read now

Articles from other publishers (12)

Frederick C. NuciforaJrJr, Marina Mihaljevic, Brian J. Lee & Akira Sawa. (2017) Clozapine as a Model for Antipsychotic Development. Neurotherapeutics 14:3, pages 750-761.
Crossref
K. P. Rakesh, C. S. Shantharam, M. B. Sridhara, H. M. Manukumar & Hua-Li Qin. (2017) Benzisoxazole: a privileged scaffold for medicinal chemistry. MedChemComm 8:11, pages 2023-2039.
Crossref
Ruben Vardanyan. 2017. Piperidine-Based Drug Discovery. Piperidine-Based Drug Discovery 241 267 .
J. Peuskens, L. Pani, J. Detraux & M. De Hert. (2014) The Effects of Novel and Newly Approved Antipsychotics on Serum Prolactin Levels: A Comprehensive Review. CNS Drugs.
Crossref
Melvin George, Radhika Amrutheshwar, Ravi Philip Rajkumar, Shivanand Kattimani & Steven Aibor Dkhar. (2013) Newer antipsychotics and upcoming molecules for schizophrenia. European Journal of Clinical Pharmacology 69:8, pages 1497-1509.
Crossref
Robert H. Howland. (2011) Update on Newer Antipsychotic Drugs. Journal of Psychosocial Nursing and Mental Health Services 49:4, pages 13-15.
Crossref
Sally A. ArifMelissa M. Mitchell. (2011) Iloperidone: A new drug for the treatment of schizophrenia. American Journal of Health-System Pharmacy 68:4, pages 301-308.
Crossref
John L. Waddington, Colm M. P. O'Tuathaigh & Gary J. Remington. 2010. Schizophrenia. Schizophrenia 483 514 .
Lesley J. Scott. (2009) Iloperidone. CNS Drugs 23:10, pages 867-880.
Crossref
L. Citrome. (2009) Iloperidone for schizophrenia: a review of the efficacy and safety profile for this newly commercialised second-generation antipsychotic. International Journal of Clinical Practice 63:8, pages 1237-1248.
Crossref
Jose de Leon. (2008) Pharmacogenomics: The Promise of Personalized Medicine for CNS Disorders. Neuropsychopharmacology 34:1, pages 159-172.
Crossref
Charles U Nnadi & Anil K Malhotra. (2008) Clinical and pharmacogenetic studies of iloperidone. Personalized Medicine 5:4, pages 367-375.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.